Start Date

5-15-2025 9:30 AM

End Date

5-15-2025 11:30 AM

Description

Background and Objective

  • Testosterone-induced acne vulgaris (TiAV) and androgenic alopecia (TiAGA) are common dermatologic effects of gender- affirming hormone therapy (GAHT) in transmasculine or non- binary individuals, with prevalence estimates ranging from 31.1% to 88% for TiAV and up to 63.3% for TiAGA. These conditions can contribute to significant psychological distress and may exacerbate gender dysphoria, underscoring the importance of affirming, evidence-based dermatologic care.
  • Despite increasing access to GAHT and the high prevalence of these conditions, there are no standardized guidelines for the management of TiAV and TiAGA, and data on dermatology trainees’ preparedness to care for this population are lacking.
  • We conducted a national survey of dermatology residents and faculty to assess educational exposure, clinical experience, comfort, and knowledge in managing TiAV and TiAGA in transmasculine/non-binary patients, with the goal of informing curricular development and improving LGBTQIA+ dermatologic care.

Keywords

acne vulgaris, transgender, transmasculine, testosterone, androgenic alopecia

Comments

Presented at the 2025 Jefferson Health Equity and Quality Improvement (HEQI) Summit.

Download

Share

COinS
 
May 15th, 9:30 AM May 15th, 11:30 AM

Dermatology Residency Education in Treatment of Testosterone-Induced Acne Vulgaris and Androgenic Alopecia in Transmasculine Individuals: A Cross-Sectional Survey of Academic Dermatologists

Background and Objective

  • Testosterone-induced acne vulgaris (TiAV) and androgenic alopecia (TiAGA) are common dermatologic effects of gender- affirming hormone therapy (GAHT) in transmasculine or non- binary individuals, with prevalence estimates ranging from 31.1% to 88% for TiAV and up to 63.3% for TiAGA. These conditions can contribute to significant psychological distress and may exacerbate gender dysphoria, underscoring the importance of affirming, evidence-based dermatologic care.
  • Despite increasing access to GAHT and the high prevalence of these conditions, there are no standardized guidelines for the management of TiAV and TiAGA, and data on dermatology trainees’ preparedness to care for this population are lacking.
  • We conducted a national survey of dermatology residents and faculty to assess educational exposure, clinical experience, comfort, and knowledge in managing TiAV and TiAGA in transmasculine/non-binary patients, with the goal of informing curricular development and improving LGBTQIA+ dermatologic care.